PATENT CLAIM ANALYSIS

Application Number: 16025835
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "100000"]

Abstract:
Described herein are compounds, compositions and methods for treatment of cancer. Also described are methods and uses for identifying subject with cancer that are suitable for treatment with the compounds, composition and methods are described herein. In one aspect of the present invention, there is provided a method of treating a subject having a cancer deficient in NMT2, comprising: administering to said subject an NMT inhibitor.

Claim (Index 8):
The method of  claim 7 , wherein said chemotherapeutic agent is CHOP, GAP-BOP, m-BACOD, ProMACE-MOPP, ProMACE-CytaBOM, MACOP-B, IMVP-16, MIME, DHAP, ESHAP, CEFF(B), CAMP, VABCD, ABDIC, CBVD, PCVP, CEP, EVA, MOPLACE, MIME, MINE, MTX-CHOP, CEM, CEVD, CAVP, EVAP, or EPOCH.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 95.0
- Lexical Diversity: 1.6087
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13971662', '14817754', '15257478', '14201184', '10699874']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7116754858567963
- 35 USC 102 Novelty (BERT): 0.5099976597118517
- Combined Prediction Score: 0.6915077032423018
- Mean Citation Score: 182.044068
- Max Citation Score: 196.92145
- Similarity Product: 120.51235696675778

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test